Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis
Based on the seven included randomized controlled clinical trials, aflibercept biosimilars demonstrated comparable safety and efficacy to the reference aflibercept. Future research requires more rigorous studies.
Authors
- Changli Liu (ORCID: https://orcid.org/0000-0002-4531-5749)
- Zixun Wang (ORCID: https://orcid.org/0000-0001-8207-9442)
- Yating Zhou (ORCID: https://orcid.org/0000-0003-2953-8384)
- Zongyue Zhan
Institutions
- Dalian Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Eye & ENT Hospital of Fudan University (CN)
- Traditional Chinese Medicine Hospital of Kunshan (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Affiliated Zhongshan Hospital of Dalian University (CN)
- Tianjin Medical University Eye Hospital (CN)
- He Eye Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.3389/fphar.2026.1719493
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00